Bristol Myers axes German launch of new cancer drug, citing pricing hurdles
Following its European approval last September, Bristol Myers Squibb has decided not to launch Opdualag, an infusion of the pharma giant’s Opdivo and new antibody relatlimab, in Germany due to pricing pressures. The drug won approval to treat advanced melanoma in adults and adolescents aged 12 years and older.
Per a Bristol Myers spokesperson, Opdualag won’t be marketed in Germany “for the foreseeable future,” as the country’s drug pricing law from 2010 makes it so that the pharma giant “sees no possibility to achieve a benefit rating from the G-BA [Gemeinsamer Bundesausschuss] for Opdualag.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.